[{"id":"4a460451-5964-49e7-8b50-20d79d3f9b89","acronym":"HEMONC CIRM IST Lung","url":"https://clinicaltrials.gov/study/NCT03546361","created_at":"2021-01-18T17:27:35.511Z","updated_at":"2025-02-25T16:07:56.707Z","phase":"Phase 1","brief_title":"CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03546361 - HEMONC CIRM IST Lung","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" PD-L1","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • ALK rearrangement","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Ad-CCL21-DC"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/08/2019","start_date":" 07/08/2019","primary_txt":" Primary completion: 01/11/2026","primary_completion_date":" 01/11/2026","study_txt":" Completion: 01/11/2027","study_completion_date":" 01/11/2027","last_update_posted":"2025-01-14"},{"id":"77630637-dadd-44d9-abcc-9d772fa60b50","acronym":"","url":"https://clinicaltrials.gov/study/NCT00601094","created_at":"2021-06-23T19:52:38.233Z","updated_at":"2024-07-02T16:36:42.474Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT00601094","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ad-CCL21-DC"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 02/26/2009","start_date":" 02/26/2009","primary_txt":" Primary completion: 05/23/2017","primary_completion_date":" 05/23/2017","study_txt":" Completion: 05/23/2017","study_completion_date":" 05/23/2017","last_update_posted":"2020-08-03"}]